Takeda debt to EBITDA ratio after Shire deal until 2023

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

Takeda new debts to EBITDA ratios targeted until 2023

Last update:

Feb 12, 2019

Author:

��ƽ�� Research Department

Region:

Worldwide

Survey time period:

From 01/01/2021 to 31/03/2023

This statistic depicts the targeted net debt to EBITDA ratio of Takeda Pharmaceutical after the Shire deal, until March 2023, by deleveraging case. The ratio of debts to EBITDA before the Shire deal in standalone deleveraging cases was 1.6.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Targeted net debt to EBITDA ratio of Takeda Pharmaceutical after Shire deal until 2023

Get in touch with us for additional information

��ƽ��